396
Participants
Start Date
September 7, 2020
Primary Completion Date
June 4, 2025
Study Completion Date
June 4, 2025
SHR-A1811
be administered via intravenous (IV) infusion
Chang Gung Memorial Hospital, Linkou, Taoyuan District
Macquarie University Hospital, Macquarie
Nucleus Network, Melbourne
Alfred Hospital, Melbourne
Seoul National University Hospital, Seoul
Peninsula and South Eastern Haematology & Oncology Group, Frankston
Southern Oncology Clinical Research Unit, Bedford Park
Asan Medical Center, Seoul
Montefiore-Einstein Center for Cancer Care, The Bronx
Seoul National University Bundang Hospital, Seongnam-si
Greenville Hospital System, Greenville
China Medical University Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
Mary Crowley Cancer Research, Dallas
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Shengjing Hospital of China medical university, Shengyang
Fudan University Shanghai cancer center, Shanghai
Fudan Unversity Zhongshan Hospital, Shanghai
Shanghai Jiao Tong University School of Medicine Renji Hospital, Shanghai
Jiangsu Province Hospital, Nanjing
Nanjing Drum Tower Hospital, Nanjing
The first affiliated hospital of bengbu medical college, Bengbu
Tianjin medical university cancer institute&hoospital, Tianjin
The second affiliated hospital Zhejiang university school of medicine, Hangzhou
Zhejiang provincial people's hospital, Hangzhou
Fujian Cancer Hospital, Fujian
Xiangya hospital central south university, Changsha
Hunan cancer hospital, Changsha
Zhongnan hospital of Wuhan university, Wuhan
Hubei cancer hospital, Wuhan
Henan cancer Hospital, Zhengzhou
Nanfang Hospital, Guangzhou
Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Sichuan Cancer Hospital, Chengdu
Shanxi Cancer Hospital, Taiyuan
Atridia Pty Ltd.
INDUSTRY
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY